Sotorasib Clinical Trials
17 recruitingDrug
Phase 28Phase 17Phase 32
Showing 1–17 of 17 trials
Recruiting
Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled480 locationsNCT05564377
Recruiting
Phase 1Phase 2
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Locally Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8+1 more
National Cancer Institute (NCI)37 enrolled6 locationsNCT07012031
Recruiting
Phase 2
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
Advanced Solid Tumors
Amgen14 enrolled9 locationsNCT07172919
Recruiting
Phase 2
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
Metastatic Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
National Cancer Institute (NCI)105 enrolled182 locationsNCT05638295
Recruiting
Phase 1
Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Metastatic Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8+1 more
City of Hope Medical Center15 enrolled2 locationsNCT06249282
Recruiting
Phase 3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Metastatic Colorectal Cancer
Amgen450 enrolled286 locationsNCT06252649
Recruiting
Phase 1
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Non-small Cell Lung CancerThoracic Tumors
Amgen500 enrolled83 locationsNCT06333951
Recruiting
Phase 2
A Study of Sotorasib in People With Non-Small Cell Lung Cancer
Non Small Lung Cancer
Memorial Sloan Kettering Cancer Center39 enrolled7 locationsNCT06582771
Recruiting
Phase 1
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
Advanced Solid Tumors
Vividion Therapeutics, Inc.220 enrolled9 locationsNCT06804824
Recruiting
Phase 2
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Gruppo Oncologico del Nord-Ovest197 enrolled1 locationNCT05845450
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Amgen750 enrolled379 locationsNCT05920356
Recruiting
Phase 1
Ladarixin With Sotorasib in Advanced NSCLC
Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
NYU Langone Health40 enrolled6 locationsNCT05815173
Recruiting
Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients
Amgen115 enrolled3 locationsNCT07143513
Recruiting
Phase 1
A Study of Sotorasib in People With Brain Tumors
Brain Tumor
Memorial Sloan Kettering Cancer Center16 enrolled7 locationsNCT06807619
Recruiting
Phase 2
Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy
Fundación GECP19 enrolled20 locationsNCT05398094
Recruiting
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
NSCLC Stage IVSex DisorderHypogonadism, Male+1 more
Fondazione Policlinico Universitario Agostino Gemelli IRCCS80 enrolled1 locationNCT06532149
Recruiting
Phase 1Phase 2
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
Solid Tumor, Adult
Effector Therapeutics30 enrolled14 locationsNCT04092673